妊娠期急性静脉血栓栓塞症接受抗凝治疗的出血风险:一项国际多数据库队列研究
该国际多数据库回顾性队列研究纳入加拿大魁北克和德国567例妊娠期急性静脉血栓栓塞症并启动治疗剂量低分子肝素(LMWH)的孕妇,比较不同LMWH类型及每日一次与每日两次给药方案的出血风险。两队列大出血发生率分别为6.5%至7.7%,最常用LMWH与其他LMWH的风险比(95%CI)在魁北克为0.9(0.3-2.5)、德国为1.4(0.5-4.1),每日一次与每日两次给药间未见显著差异。作者认为LMWH类型和给药频率可能不影响出血风险,但需进一步研究。
要点
- 魁北克和德国两队列大出血发生率分别为6.5%至7.7%。
- 最常用LMWH与其他LMWH的风险比(95%CI)魁北克0.9(0.3-2.5)、德国1.4(0.5-4.1)。
- 每日一次与每日两次给药方案间未发现出血风险显著差异。
核心结论
- 该国际多数据库队列研究提供了妊娠期静脉血栓栓塞症治疗中使用LMWH相关出血的基于人群的发生率。
- 作者认为,尽管属于假设生成性结果,LMWH类型和给药频率可能不影响妊娠期静脉血栓栓塞症患者的出血风险。
- 作者指出需进一步研究探索抗凝策略以优化结局并减少出血并发症。
研究设计与样本
- 国际多数据库回顾性队列研究,使用加拿大魁北克和德国的人群级医疗数据。
- 纳入妊娠期急性静脉血栓栓塞症且在 incident VTE 后15天内启动治疗剂量LMWH的孕妇。
- 研究队列共567例孕妇(德国n=308;魁北克n=259)。
- 使用Cox比例风险模型比较不同LMWH相关的大出血风险。
主要发现
- 两队列大出血发生率分别为6.5%至7.7%。
- 最常用LMWH与其他LMWH的风险比(95%CI)在魁北克为0.9(0.3-2.5),在德国为1.4(0.5-4.1)。
- 每日一次与每日两次给药方案之间未发现出血风险显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需进一步研究探索抗凝策略以优化结局并减少出血并发症。
- 作者称该研究结果属于假设生成性(hypothesis-generating)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism, is a major cause of maternal mortality. Low-molecular-weight heparin (LMWH) is the mainstay of therapy for VTE during pregnancy. However, the effects of different LMWH types and dosing regimens on bleeding risk remain unclear. OBJECTIVES: To compare the risk of major bleeding among pregnant women with acute VTE treated with the most used therapeutic dose LMWH, dalteparin in Québec and enoxaparin in Germany, vs other LMWHs. We also examined the impact of once-daily vs. twice-daily LMWH dosing on bleeding outcomes. METHODS: This multinational retrospective cohort study used population-level healthcare data from Québec, Canada, and Germany and included women with acute VTE during pregnancy who initiated therapeutic doses of LMWH within 15 days of an incident VTE. We used Cox proportional hazards models to compare the risk of major bleeding associated with different LMWHs. RESULTS: The study cohort included 567 pregnant women (Germany: n = 308; Québec: n = 259) with VTE treated with LMWH. Major bleeding occurred in 6.5% to 7.7% of patients in both cohorts. The hazard ratios (95% CIs) for the most prescribed LMWH vs other LMWHs were 0.9 (0.3-2.5) in Québec and 1.4 (0.5-4.1) in Germany. No significant differences in bleeding risk were found between once-daily and twice-daily dosing schedules. CONCLUSION: Our multinational cohort study provided population-based incidence rates for bleeding related to LMWH use during VTE treatment in pregnancy. Moreover, while hypothesis-generating, our findings suggest that the LMWH type and dosing frequency may not influence bleeding risk in pregnant women with VTE. Further research is necessary to explore anticoagulation strategies to optimize outcomes and minimize bleeding complications.
引用
- Simard C, Malhamé I, Filliter C, et al. The risk of bleeding in pregnant women with acute venous thromboembolism treated with anticoagulants: an international multidatabase cohort study. J Thromb Haemost. 2025. PMID: 40653091. doi:10.1016/j.jtha.2025.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。